Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GlucoTab

Financiado

Cerrado

A Novel ICT Assistant Solution for de Risked Management of Insulin Dosing and Bl...

A Novel ICT Assistant Solution for de Risked Management of Insulin Dosing and Blood Glucose Levels in Hospitalized Patients with Type 2 Diabetes "Despite being responsible for up to 1/3 of admissions, the management of type 2 diabetes in hospital wards is still extremely challenging. European clinical guidelines recommend prescription of ""basal-bolus insulin therapy"" as... ver más

28/02/2017

DCS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

DECIDE CLINICAL SOFTWARE GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-02-28

SMEInst-01-2016-2017: Open Disruptive Innovation Scheme

I+D

Cerrada hace 9 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

DCS

50.00K€ | Lider

Proyectos interesantes

CLINICIP

Medical Technol...

Data Science

11M€ Cerrado

CPP2021-008659

Medical Technol...

Software

275K€ Cerrado

OPEN

Medical Technol...

Data Science

1M€ Cerrado

PDC2021-121470-C21

Medical Technol...

Data Science

69K€ Cerrado

PDC2021-121470-C22

Medical Technol...

Data Science

69K€ Cerrado

REACTION

Medical Technol...

Data Science

16M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 3 meses Fecha Inicio: 2016-11-17
Fecha Fin: 2017-02-28

Líder del proyecto

DECIDE CLINICAL SOFTWARE GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Despite being responsible for up to 1/3 of admissions, the management of type 2 diabetes in hospital wards is still extremely challenging. European clinical guidelines recommend prescription of ""basal-bolus insulin therapy"" as it is the most flexible, adaptable and precise regimen available to mimic the physiological secretion of insulin. However, it requires a patient-centric approach with multiple daily follow-ups. Since both persistent hypoglycemia (due to incorrect medication) and hyperglycemia (due to disease) are hazardous, diabetic care requires day-to-day decisions combining medical judgment and clinical findings. This overwhelming task is even more complicated due to the current inefficient methods that rely on by-hand calculations and paper-based charts. Thus, management becomes a complex task, increasing the workload for the already saturated personnel. Most importantly, it increases the overall risk of medical errors. Indeed, 42% in-hospital days are impacted by treatment errors, wrong blood glucose measurements or lack of adjustments on insulin dosing. Thus, +50% of patients suffer at least one medication error during their stay. In response, we have created GlucoTab, an ICT-based software able to assist on the arduous decision-making process daily incurred in the management of type 2 diabetes. GlucoTab will automate and standardize task management, reducing risks, costs and easing the personnel's work-flow. Conceived as a medical device, our product is able to offer guidance on the most suitable insulin dosing regimen for a patient. By enabling the full integration of the patient's bedside management with the general hospital information system, we believe that GlucoTab encloses a cost-efficient solution that will allow hospitals and healthcare systems to face the alarming rising incidence of diabetes. In turn, GlucoTab will provide us estimated cumulative revenues of €7.7 M after enrolling +13,600 beds within five years from market launch."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores